{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ulcer+Gastrointestinal&page=2", "query": { "condition": "Ulcer Gastrointestinal", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ulcer+Gastrointestinal&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:45:15.850Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01805791", "title": "A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "HMPL-004 1800 mg/day", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "HMPL-004 2400 mg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 201, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 1, "location_summary": "Agawam, Massachusetts", "locations": [ { "city": "Agawam", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01805791" }, { "nct_id": "NCT04985968", "title": "The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Cobitolimod 250 mg", "type": "DRUG" }, { "name": "Cobitolimod 500 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InDex Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2021-11-24", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 25, "location_summary": "Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985968" }, { "nct_id": "NCT07590518", "title": "VR Therapies for IBD", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Disease (IBD)", "Ulcerative Colitis (UC)", "Crohn Disease (CD)", "Anxiety" ], "interventions": [ { "name": "Distraction VR", "type": "DEVICE" }, { "name": "VR/AI CBT", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Brennan Spiegel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2026-06", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 2, "location_summary": "Los Angeles, California • Chicago, Illinois", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07590518" }, { "nct_id": "NCT03398148", "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "risankizumab IV", "type": "DRUG" }, { "name": "placebo for risankizumab", "type": "DRUG" }, { "name": "risankizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1558, "start_date": "2018-03-07", "completion_date": "2023-05-11", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 82, "location_summary": "Coronado, California • Irvine, California • La Jolla, California + 63 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03398148" }, { "nct_id": "NCT02316678", "title": "Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colitis, Ulcerative", "Inflammatory Bowel Diseases", "Crohn's Disease" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9573, "start_date": "2014-09", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316678" }, { "nct_id": "NCT00343850", "title": "Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Asacol (mesalamine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-09", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343850" }, { "nct_id": "NCT00488774", "title": "An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Golimumab 1 mg per kg", "type": "DRUG" }, { "name": "Golimumab 2 mg per kg", "type": "DRUG" }, { "name": "Golimumab 4 mg per kg", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2007-08", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2013-06-14", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 36, "location_summary": "Orange, California • Roseville, California • Littleton, Colorado + 33 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Bristol", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488774" }, { "nct_id": "NCT04806620", "title": "Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Post-Acute COVID-19 Syndrome", "ME/CFS", "Rheumatic Arthritis", "Juvenile Rheumatoid Arthritis (JRA)", "Psoriatic Arthritis (PsA)", "Ankylosing Spondylitis (AS)", "Autoimmune Encephalitis", "Celiac Disease", "Celiac Disease in Children", "Chronic Lyme Disease", "Post-treatment Lyme Disease Syndrome", "Crohn's Disease", "Dysautonomia", "Anorexia Nervosa", "Bulimia Nervosa", "ARFID", "Avoidant / Restrictive Food Intake Disorder", "Ehlers Danlos Syndrome", "Endometriosis", "Fibromyalgia (FM)", "Long COVID", "Lupus", "Migraines", "Mast Cell Activation Syndrome", "Multiple Sclerosis", "Myalgic Encephalomyelitis (ME)", "Myasthenia Gravis, Generalized", "Myasthenia Gravis in Children", "Narcolepsy", "Obsessive Compulsive Disorder (OCD)", "PANDAS", "Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)", "POTS - Postural Orthostatic Tachycardia Syndrome", "General Anxiety Disorder, Social Anxiety Disorder", "PTSD - Post Traumatic Stress Disorder", "Psoriasis", "Traumatic Brain Injury", "Tourette's Syndrome", "Inflammatory Bowel Disease (IBD)", "Autoimmune Diseases", "Neurological Diseases or Conditions", "Psychiatric Disorder", "Sjogren's Syndrome", "Ulcerative Colitis and Crohn's Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Brain Inflammation Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 10000, "start_date": "2023-07-05", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 1, "location_summary": "Delafield, Wisconsin", "locations": [ { "city": "Delafield", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04806620" }, { "nct_id": "NCT07198113", "title": "COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ulcerative Colitis, Pediatric", "Inflammatory Bowel Diseases", "Crohn Disease" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 1100, "start_date": "2025-11-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 4, "location_summary": "Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07198113" }, { "nct_id": "NCT03414788", "title": "Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Inflammatory Bowel Disease" ], "interventions": [ { "name": "PF 06687234", "type": "BIOLOGICAL" }, { "name": "[124I]IB PF 06687234", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2020-12-07", "completion_date": "2022-02-01", "has_results": false, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-06-11T04:45:15.850Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414788" } ] }